secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001437749-24-027012
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Q2 2024 net loss $2.3M, cash $50.9M; DLB trial enrolled, topline Dec 2024
--------------------------------------------------------------------------------

- Net loss $2.3M in Q2 2024 vs $1.4M in Q2 2023; operating loss $3.0M vs $1.2M.
- Cash, equivalents and marketable securities $50.9M at June 30, 2024, up from $7.8M at Dec 31, 2023.
- Completed enrollment in Phase 2b RewinD-LB trial (neflamapimod for early-stage DLB) in June 2024; topline data expected Dec 2024.
- Private placement in April 2024 raised $50M upfront, with potential total proceeds up to $149.4M.
- NIA grant revenue $5.6M for H1 2024 vs $3.1M for H1 2023; cash runway extended through 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924027012/0001437749-24-027012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924027012/crvo20240815_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-027012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer